For optimal viewing, please use a desktop or laptop computer. Prescribing information links can be found at the top of the page. Adverse event reporting can be found at the bottom of the page.

Two Phase 3 clinical trials. Two different chemotherapy regimens.
One focus: VYLOY + platinum and fluoropyrimidine chemotherapy to help improve survival.1

efficacy banner desktop
efficacy banner mobile
Open anchor link menu
Close anchor link menu

Study Design

In the GLOW Phase 3 trial, VYLOY + CAPOX was evaluated against placebo + CAPOX1–3

glow graph 1 desktop
glow graph 1 mobile

Key Eligibility Criteria2¶

  • Aged 18 years or older, with CLDN18.2-positive,* HER2-negative, previously untreated, locally advanced unresectable 
or metastatic G/GEJ adenocarcinoma
  • ECOG performance status 0 or 1
  • Radiological evaluable disease per RECIST v1.1
  • Adequate organ function

Key Exclusion Criteria2¶

  • Received prior systemic chemotherapy for locally advanced unresectable or metastatic G/GEJ adenocarcinoma
  • Significant cardiovascular disease**
  • Complete or partial gastric outlet syndrome
  • Positive test for HIV, or known hepatitis B or C infection
  • History of CNS metastases

*Tumour expresses CLDN18.2 in ≥75% of tumour cells demonstrating moderate to strong membranous staining as determined by central IHC testing.2

†HER2-negative tumour as determined by local or central testing on a gastric or GEJ tumour specimen.2

‡No prior systemic chemotherapy. Subject may have received other systemic anti-cancer treatments as long as they were completed 6 months prior 
to randomisation.2

§VYLOY was administered at a loading dose of 800 mg/m2 IV on Cycle 1 Day 1 followed by 600 mg/m2 IV every 3 weeks. Patients received either VYLOY or placebo and CAPOX (capecitabine/oxaliplatin) treatment for a total of 8 cycles (21 days per cycle) until IRC confirmed disease progression. Oxaliplatin was administered on Day 1 of each cycle, whereas capecitabine was taken twice daily on Days 1 through 14. After a maximum of 8 cycles of treatment, patients continued to receive capecitabine twice daily on Days 1 through 14 of each cycle at the investigator’s discretion until disease progression, development of toxic effects, start of another anti-cancer treatment or other discontinuation criteria were met, as specified in the protocol.1,2

||Placebo was administered on Cycle 1 Day 1 and every 3 weeks thereafter.1,2

For the full eligibility and exclusion criteria, please refer to the Shah MA et al, 2023 study.

**Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months before randomisation.2

CAPOX=capecitabine/oxaliplatin; CLDN18.1=Claudin 18.2; CNS=central nervous system; ECOG=Eastern Cooperative Oncology Group; G/GEJ=gastric/gastro-oesophageal junction; HER2=human epidermal growth factor receptor 2; HIV=human immunodeficiency virus; IHC=immunohistochemistry; IRC=independent review committee.

In the GLOW Phase 3 trial, VYLOY (zolbetuximab) + CAPOX significantly improved PFS vs placebo + CAPOX1

Median PFS was 8.2 months with VYLOY + CAPOX vs 6.8 months with placebo + CAPOX (HR=0.69 [95% CI: 0.54–0.87]; P=0.0014)1

spotlight graph 2 desktop
spotlight graph 2 mobile
Sustained benefits in PFS were also seen at 12, 18 and 24 months for VYLOY + CAPOX vs placebo + CAPOX1
Duration VYLOY + CAPOX Placebo + CAPOX
12-month PFS (%) (95% CI) 34.9 (27.8–42.1) 19.1 (13.5–25.5)
18-month PFS (%) (95% CI) 23.9 (17.1–31.4) 10.6 (5.7–17.3)
24-month PFS (%) (95% CI) 14.5 (6.2–26.2) 7.3 (3.0–14.2)

*Per RECIST version 1.1 as determined by independent review committee in full analysis set.1

†2-sided p-value based on 2-sided log-rank test.1

ARR=absolute risk reduction; CAPOX=capecitabine/oxaliplatin; CI=confidence interval; HR=hazard ratio; RECIST=Response Evaluation Criteria in Solid Tumours.

In the GLOW Phase 3 trial, OS significantly improved with 
first-line VYLOY + CAPOX vs placebo + CAPOX1

Median OS was 14.4 months with VYLOY + CAPOX vs 12.2 months with placebo + CAPOX (HR=0.77 [95% CI: 0.62–0.97]; P=0.0236).1

spotlight graph 5 desktop
spotlight graph 5 mobile
Sustained benefits in OS were also seen at 12, 18 and 24 months for VYLOY + CAPOX vs placebo + CAPOX1
Duration VYLOY + CAPOX Placebo + CAPOX
12-month OS (%) (95% CI) 57.5 (50.7–63.8) 50.8 (44.1–57.1)
18-month OS (%) (95% CI) 38.1 (31.0–45.2) 28.1 (22.0–34.7)
24-month OS (%) (95% CI) 28.9 (21.8–36.5) 17.4 (11.6–24.1)

*2-sided p-value based on 2-sided log-rank test.1

ARR=absolute risk reduction; CAPOX=capecitabine/oxaliplatin; CI=confidence interval.

In the GLOW Phase 3 trial, response rates were similar between VYLOY + CAPOX and placebo + CAPOX2*

Complete response was 3.5% with VYLOY + CAPOX (n=9) vs 2.0% with placebo + CAPOX (n=5).2

spotlight graph 3 desktop
spotlight graph 3 mobile

Median duration of response was 6 months with VYLOY + CAPOX vs 6 months with placebo + CAPOX.2

spotlight graph 4 desktop
spotlight graph 4 mobile

*Per RECIST version 1.1 as determined by independent review committee in full analysis set.2

CAPOX=capecitabine/oxaliplatin; CI=confidence interval; CR=complete response; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumours.

GLOW patient population1,2

Demographic and baseline characteristics were generally well balanced between groups.2

    

BASELINE CHARACTERISTICS VYLOY + CAPOX
(n=254) PLACEBO + CAPOX
(n=253)
Age, years Median (range) 61 (22 to 82) 59 (21 to 83)
≥18 to ≤64 (%) 66 68
≥65 (%) 34 32
Race (%) White 37 36
Asian 63 64
American Indian or Alaskan 0 0
Black or African American 0 0
Other 0 0
Gender (%) Male 63 62
Female 37 38
ECOG
performance status		 0 (%) 43 43
1 (%) 57 57
Missing data (n) 1 1
Body surface area (m2) Mean (range) 1.7 (1.2 to 2.3) 1.7 (1.1 to 2.3)
Time from diagnosis (days) Median (range) 44 (12 to 2,396) 44 (2 to 6,010)
Tumour location Distal (%) 39 38
Proximal (%) 35 37
Unknown (%) 26 25
Missing (n) 0 0

Tumour type
(Lauren classification) Diffuse (%) 34 40
Intestinal (%) 14 16
Other (%) 13 11
Mixed (%) 8 8
Unknown (%) 30 25
Missing (n) 1 0
Organs with metastases (%)2 0–2 74 74
≥3 26 26
Primary site (%)3 Stomach 86 83
Gastro-oesophageal junction 14 17
Region Asia 62 63
Non-Asia 38 38
Previous gastrectomy Yes 30 30
No 71 70
Measurable disease Yes 77 81
No 23 19

Adapted from VYLOY Summary of Product Characteristics and Shah et al, 2023.

CAPOX=capecitabine/oxaliplatin; ECOG=Eastern Cooperative Oncology Group.

GLOW: safety data

Adverse reactions reported in ≥10% of patients (any grade)2*

TREATMENT-EMERGENT ADVERSE EVENTS2 VYLOY + CAPOX (n=254) PLACEBO + CAPOX (n=249)
ANY GRADE, n (%) GRADE ≥3, n (%) ANY GRADE, n (%) GRADE ≥3, n (%)
Any adverse event 251 (99) 185 (73) 244 (98) 174 (70)
Nausea 174 (69) 22 (9) 125 (50) 6 (2)
Vomiting 168 (66) 31 (12) 77 (31) 9 (4)
Decreased appetite 105 (41) 17 (7) 84 (34) 4 (2)
Anaemia 90 (35) 27 (11) 91 (37) 28 (11)
Diarrhoea 80 (32) 15 (6) 86 (35) 18 (7)
Neutrophil count decreased 70 (28) 26 (10) 59 (24) 24 (10)
Aspartate
aminotransferase
increased		 63 (25) 6 (2) 72 (29) 7 (3)
Platelet count
decreased		 61 (24) 19 (8) 60 (24) 20 (8)
Hypoalbuminaemia 57 (22) 8 (3) 35 (14) 4 (2)
Peripheral sensory
neuropathy		 56 (22) 1 (<1) 56 (23) 6 (2)
White blood cell count
decreased		 51 (20) 5 (2) 39 (16) 9 (4)
Neutropenia 50 (20) 18 (7) 35 (14) 7 (3)
Weight decreased 50 (20) 1 (<1) 25 (10) 1 (<1)
Alanine
aminotransferase increased		 48 (19) 2 (1) 52 (21) 7 (3)
Palmar-plantar
erythrodysaesthesia syndrome		 41 (16) 4 (2) 49 (20) 9 (4)
Abdominal pain 40 (16) 1 (<1) 54 (22) 4 (2)
Constipation 39 (15) - 52 (21) -
Fatigue 34 (13) 7 (3) 42 (17) 9 (4)
Pyrexia 34 (13) 1 (<1) 23 (9) 0
Asthenia 33 (13) 7 (3) 32 (13) 3 (1)
Malaise 31 (12) 1 (<1) 22 (9) 0
Hypoesthesia 30 (12) 1 (<1) 30 (12) 0
Thrombocytopenia 28 (11) 7 (3) 31 (12) 7 (3)
Insomnia 27 (11) - 16 (6) -
Oedema peripheral 26 (10) 1 (<1) 6 (2) 0
  • Serious TEAEs: 47% (n=120) with VYLOY + CAPOX vs 50% (n=124) with placebo + CAPOX2
  • TEAEs leading to discontinuation of VYLOY or placebo: 20% (n=51) with VYLOY + CAPOX vs 15% (n=36) with placebo + CAPOX2
  • TEAEs leading to death were reported in 11% (n=27) of patients with VYLOY + CAPOX (vs 13% (n=32) in patients with placebo + CAPOX)2

Nausea and vomiting occurred more often in the first cycle of treatment and decreased in incidence in the cycles that followed in VYLOY + CAPOX and placebo + CAPOX.1,3

Refer to the Summary of Product Characteristics for the full safety profile of VYLOY.

*Grades 3 to 5 include serious, life-threatening and fatal adverse events.2

CAPOX=capecitabine/oxaliplatin; TEAE=treatment-emergent adverse event.

Find out how IHC testing for CLDN18.2 helps identify patients who may be candidates for VYLOY + chemotherapy.

CLDN18.2=Claudin 18.2; IHC=immunohistochemistry.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd. on 0800 783 5018.

The above link will take you to a non-Astellas website. Astellas does not endorse or accept liability for sites controlled by third-parties.

References:

  1. VYLOY Summary of Product Characteristics.
  2. Shah MA, Shitara K, Adani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 GLOW trial. Nat Med 2023;29(8):2133–41.
  3. Shah MA, Shitara K, Adani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 GLOW trial. Supplement in Nat Med 2023;29(8):2133–41.

MAT-GB-ZOL-2024-00087 | Date of preparation: January 2026

Indication

Important Safety Information

Indication

VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.

SAFETY PROFILE

The safety of VYLOY was evaluated in two Phase 2 studies (FAST, ILUSTRO) and two Phase 3 studies (SPOTLIGHT, GLOW) in 631 patients who received at least one dose of VYLOY 800 mg/m2 as a loading dose followed by 600 mg/m2 subsequent doses every 3 weeks in combination with fluoropyrimidine- and platinum-containing chemotherapy. The median duration of exposure to zolbetuximab was 174 days (range: 1 to 1,791 days).

Serious adverse events occurred in 45% of patients treated with VYLOY and/or fluoropyrimidine- and platinum‑containing chemotherapy. The most common serious adverse reactions (≥2%) were vomiting (6.8%) and nausea (4.9%).

Adverse reactions observed during clinical studies

isi

Frequency categories are defined as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

  • Thirty-seven percent of patients permanently discontinued VYLOY for adverse events; the most common adverse reactions (≥2%) leading to dose discontinuation were vomiting (5.4%) and nausea (4.3%).
  • Adverse events leading to dose interruption of VYLOY and/or fluoropyrimidine- and platinum‑containing chemotherapy occurred in 73% of patients; the most common adverse reactions (≥2%) leading to dose interruption were vomiting (29.3%), nausea (28.4%) and decreased appetite (3.6%).
  • The most common adverse reactions (≥2%) leading to dose rate reduction of the VYLOY and/or fluoropyrimidine- and platinum-containing chemotherapy infusion were nausea (9.7%) and vomiting (7.8%).

Contraindications

  • Hypersensitivity to the active substance or to any of the following excipients: Arginine, Phosphoric acid, Sucrose, Polysorbate 80

Interaction with other medicinal products and other forms of interaction

  • Zolbetuximab is not a cytokine modulator and there are no known effects of its mechanism of action on cytochrome P450 or drug transporters; therefore, no in vitro or in vivo drug-drug interaction or transporter studies have been conducted
  • Based on a Phase 2 study, co-administration of zolbetuximab with mFOLFOX6 did not show a clinically meaningful change in drug exposure of zolbetuximab, oxaliplatin or 5-fluorouracil (5-FU). Therefore, no dose adjustment is required for zolbetuximab and mFOLFOX6 when used in combination. This finding is also expected to be applicable to CAPOX, which contains oxaliplatin and capecitabine (a prodrug of 5-FU), therefore no dose adjustment is required for zolbetuximab and CAPOX when used in combination

Fertility, pregnancy and lactation

  • There are no data on the use of zolbetuximab in pregnant women. VYLOY should only be given to a pregnant woman if the benefit outweighs the potential risk

    - No adverse effects were observed in an animal reproductive and developmental study with intravenous administration of zolbetuximab to pregnant mice during organogenesis. Based on AUC, the doses administered in this study were up to approximately 1.8 times higher than human exposure at the recommended therapeutic dose of 600 mg/m2
  • There are no data on the presence of zolbetuximab in human milk, the effects on the breastfed child or the effects on milk production. Breastfeeding is not recommended during treatment with VYLOY

    - Because many drugs, including antibodies are excreted in human milk and because of the potential for serious adverse reactions in a breastfed child, breastfeeding is not recommended during treatment with VYLOY
  • The effect of VYLOY on male and female fertility is unknown

    - Studies to evaluate the effect of zolbetuximab on fertility have not been performed

Traceability

  • In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded

WARNINGS AND PRECAUTIONS

 

HYPERSENSITIVITY REACTIONS

  • In the integrated safety analysis, all grade hypersensitivity reactions such as anaphylactic reaction and drug hypersensitivity occurred in the VYLOY + fluoropyrimidine- and platinum-containing chemotherapy arm [0.5% (3/631), 1.6% (10/631)] compared with the fluoropyrimidine- and platinum-containing chemotherapy + placebo arm [0.8% (5/611), 1.6% (10/611)]
  • The median time to first onset of anaphylactic reaction or drug hypersensitivity with VYLOY + fluoropyrimidine- and platinum-containing chemotherapy was 22 days or 113 days, respectively
  • Three patients (0.5%) permanently discontinued VYLOY due to anaphylactic reaction
  • Severe (Grade 3) anaphylactic reaction and drug hypersensitivity occurred at a similar frequency in the VYLOY + fluoropyrimidine- and platinum-containing chemotherapy arm [0.5% (3/631), 0.2% (1/631)] compared with the fluoropyrimidine- and platinum-containing chemotherapy + placebo arm [0.3% (2/611), 0.2% (1/611)]
  • Dose interruption of VYLOY was experienced due to drug hypersensitivity in six patients (1%). The infusion rate was reduced for VYLOY or fluoropyrimidine- and platinum-containing chemotherapy in one patient (0.2%) due to drug hypersensitivity

Special warnings and precautions for use

  • Monitor patients during and after infusion with VYLOY (at least 2 hours, or longer if clinically indicated) for hypersensitivity reactions with symptoms and signs that are highly suggestive of anaphylaxis (urticaria, repetitive cough, wheeze and throat tightness/change in voice)
  • If an anaphylactic reaction occurs, administration of VYLOY should be immediately and permanently discontinued and appropriate medical therapy administered
  • For any Grade 3 or 4 hypersensitivity reaction or hypersensitivity reaction with features of anaphylaxis, administration of VYLOY should be immediately and permanently discontinued and appropriate medical therapy instituted based on the type of reaction
  • For any Grade 2 hypersensitivity reaction, interrupt the VYLOY infusion until Grade ≤1, then resume the infusion at a reduced infusion rate for the remaining infusion. Pre-medicate the patient with antihistamines for the next infusion, and closely monitor the patient for symptoms and signs of a hypersensitivity reaction. The infusion rate may be gradually increased as tolerated

INFUSION-RELATED REACTION (IRR)

  • In the integrated safety analysis, all grade IRR occurred in the VYLOY + fluoropyrimidine- and platinum-containing chemotherapy arm at 3.2% (20/631) compared with fluoropyrimidine- and platinum-containing chemotherapy + placebo at 1.1% (7/611)
  • The median time to first onset of infusion-related reaction with VYLOY + fluoropyrimidine- and platinum-containing chemotherapy was 22 days
  • An IRR led to permanent discontinuation of VYLOY in 4 (0.6%) patients and dose interruption in 10 (1.6%) patients. The infusion rate was reduced for VYLOY or fluoropyrimidine- and platinum-containing chemotherapy in 2 patients (0.3%) due to an IRR
  • Severe (Grade 3) IRRs occurred more frequently in the VYLOY + fluoropyrimidine- and platinum-containing chemotherapy arm [0.5% (3/631)] compared with fluoropyrimidine- and platinum-containing chemotherapy + placebo [0% (0/611)]

Special warnings and precautions for use

  • Monitor patients for signs and symptoms of infusion-related reaction including nausea, vomiting, abdominal pain, salivary hypersecretion, pyrexia, chest discomfort, chills, back pain, cough and hypertension. These signs and symptoms are usually reversible with the interruption of the infusion
  • For Grade 3 or 4 IRRs, administration of VYLOY should be immediately and permanently discontinued and appropriate medical therapy instituted
  • For Grade 2 IRRs, interrupt the VYLOY infusion until Grade ≤1, then resume the infusion at a reduced infusion rate for the remaining infusion. Pre-medicate the patient with antihistamines for the next infusion, and closely monitor the patient for symptoms and signs of an IRR. The infusion rate may be gradually increased as tolerated

NAUSEA AND VOMITING

  • In the integrated safety analysis, all grade nausea and vomiting occurred more frequently in the VYLOY in combination with fluoropyrimidine- and platinum-containing chemotherapy arm [77.2% (487/631), 66.9% (422/631)] compared with the placebo in combination with fluoropyrimidine- and platinum-containing chemotherapy arm [58.9% (360/611), 36.8% (225/611)]
  • Severe (Grade 3) nausea and vomiting in the VYLOY in combination with fluoropyrimidine- and platinum-containing chemotherapy and placebo in combination with fluoropyrimidine- and platinum-containing chemotherapy arms occurred at the following freHYPERSENSITIVITY REACTIONSquencies: nausea [11.6% (73/631) and 4.7% (29/611)] and vomiting [13.6% (86/631) and 4.7% (29/611)]
  • The median time to first onset of nausea or vomiting with VYLOY in combination with fluoropyrimidine- and platinum-containing chemotherapy was 1 day or 1 day, respectively
  • Nausea led to permanent discontinuation of VYLOY in 27 (4.3%) patients and dose interruption in 179 (28.4%) patients. Vomiting led to permanent discontinuation of VYLOY in 34 (5.4%) patients and dose interruption in 185 (29.3%) patients. The infusion rate was reduced for VYLOY or fluoropyrimidine- and platinum-containing chemotherapy in 61 patients (9.7%) due to nausea and in 49 patients (7.8%) due to vomiting

Special warnings and precautions for use

  • Nausea and vomiting occurred more often during the first cycle of treatment but decreased in incidence with subsequent cycles of treatment
  • To prevent nausea and vomiting, pre-treatment with antiemetics is recommended prior to each infusion of VYLOY
  • During and after infusion, patients should be monitored and managed using standard of care, including antiemetics or fluid replacement, as clinically indicated
  • For Grade 4 vomiting, permanently discontinue treatment with VYLOY
  • For Grade 2 or 3 nausea or vomiting, interrupt the VYLOY infusion until Grade ≤1, then resume at a reduced infusion rate for the remaining infusion. For the next infusion, administer per the recommended infusion rates, and closely monitor the patient for symptoms and signs of nausea or vomiting. The infusion rate may be gradually increased as tolerated

 

Refer to the Summary of Product Characteristics for the full safety profile of VYLOY.